Van Reekum R, Bayley M, Garner S, Burke I M, Fawcett S, Hart A, Thompson W
McMaster University, Hamilton, Ontario, Canada.
Brain Inj. 1995 Jan;9(1):49-53. doi: 10.3109/02699059509004571.
Severe amotivation, apathy, and abulia, significantly retard rehabilitation following traumatic brain injury. Preliminary, uncontrolled research has suggested possible benefit with amantadine for this behavioural syndrome. This N of 1, double-blind, placebo-controlled study employed amantadine 100 mg three times daily in one such patient. Therapists and nurses completed inventories scoring efforts towards initiation of therapeutic activities during each session, progress in therapy, and participation in therapy. Four treatment periods (two active medication, two placebo), of 2 weeks duration, were completed. Across four therapists, and for both treatment pairs, the average effect score increased from 0.86 on placebo to 1.74 on amantadine (possible range 0-6, 3 = 'average'). There were no side-effects. The study suggests possible benefit with amantadine for patients with amotivational syndrome after traumatic brain injury; a randomized clinical trial appears warranted and required.
严重的动力缺乏、冷漠和意志缺失会显著延缓创伤性脑损伤后的康复进程。初步的非对照研究表明金刚烷胺可能对此行为综合征有益。这项单病例、双盲、安慰剂对照研究对一名此类患者使用了每日三次、每次100毫克的金刚烷胺。治疗师和护士完成了量表，对每个疗程中开展治疗活动的努力程度、治疗进展及参与治疗情况进行评分。完成了四个为期2周的治疗期（两个活性药物期，两个安慰剂期）。在四位治疗师中，对于两组治疗，平均效应评分从安慰剂组的0.86提高到金刚烷胺组的1.74（可能范围为0 - 6，3 = “平均”）。未出现副作用。该研究表明金刚烷胺可能对创伤性脑损伤后动力缺乏综合征患者有益；一项随机临床试验似乎是必要且必需的。
